A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on the management of patients ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

Topline data were announced from a phase 3 trial evaluating tarlatamab-dlle (Imdelltra ®) for the treatment of small cell lung cancer (SCLC) in patients who progressed on or after a single line ...

The drug is being developed for the treatment of small cell lung cancer and neuroendocrine carcinoma, including neuroendocrine prostate cancer. The multi-center, first-in-human, open-label, phase 2/3 ...

Small-cell lung cancer is an aggressive cancer with a 5-year survival below 5% among patients with extensive-stage disease. 1 Although most patients’ tumors respond to frontline platinum-based ...

They looked at blood samples from 41 patients with lung cancer (mostly non-small cell) treated with curative intent for stage I to III disease (mostly stage III). Median follow-up was 35 months.